Published in Hematology Week, September 19th, 2005
This phase 2 trial, also known as Anticoagulation with rNAPc2 To Help Eliminate MACE (ANTHEM/TIMI) 32, is a single-arm, open-label study that is evaluating the efficacy and safety of rNAPc2 by reducing the dose of, and ultimately replacing, unfractionated heparin in patients being treated for ACS.
The study will include from 50 to 100 patients and is being conducted in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.